We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Icosavax's computationally designed virus-like particle (VLP) vaccine platform as a potential first-in-class vaccine for the respiratory syncytial virus (RSV).
